Emergency Medicine Cases – Where the Experts Keep You in the Know. For complete episodes please visit emergencymedicinecases.com
Richard S. Finn, MD - How I Think, How I Treat: Remodeling the HCC Treatment Algorithm With New and Emerging Monotherapy, Combination, and Multimodal Approaches
Manage episode 287637588 series 9912
著作 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education の情報はPlayer FM及びコミュニティによって発見されました。著作権は出版社によって所持されます。そして、番組のオーディオは、その出版社のサーバから直接にストリーミングされます。Player FMで購読ボタンをタップし、更新できて、または他のポッドキャストアプリにフィードのURLを貼り付けます。
Go online to PeerView.com/AXW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Experts in liver cancer discuss changes to the treatment algorithm for advanced hepatocellular carcinoma (HCC), with an emphasis on selecting and sequencing treatment strategies based on the evidence, guidelines, and patient-related factors. Topics include pivotal safety and efficacy data on multikinase inhibitors, antiangiogenic agents, and immune checkpoint inhibitors used as monotherapy and in combinations with other immunotherapeutic agents or TKIs, clinical trials testing novel strategies and systemic therapies in various settings, and insights from the faculty members on translating treatment advances into clinical practice. Upon completion of this activity, participants should be better able to: Review pivotal safety and efficacy data on available multikinase inhibitors, antiangiogenic agents, single-agent checkpoint inhibitors, and immunotherapy combinations as first- and second-line treatment options for advanced HCC, Assess the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and combination with targeted therapy, in the advanced HCC disease setting, Summarize ongoing clinical trials testing systemic therapies in the adjuvant setting and in combination with locoregional therapies across the disease spectrum of HCC, Develop safe and effective personalized treatment algorithms for patients with HCC, across multiple lines of therapy, based on current clinical evidence, guideline recommendations, treatment history, underlying liver disease, AFP levels, and individual patient needs.